TICKERNERD
Menu
HUMAHUMAHealthcare · Biotechnology

HUMA Stock Forecast: Humacyte, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$0.47
−0.04% on the day

The 6 Wall Street analysts covering Humacyte, Inc. hold a median 12-month price target of $1.13 — +139.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 29 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$130.6M
Ticker Nerd rank
17/ 100
Median analyst target
$1.13
Analysts covering
6
Revenue$406K+34.9% y/y
Operating income−$27.0M
Net income−$36.8M
Free cash flow−$22.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+13.8%
1M
−11.9%
YTD
−51.1%
1Y
−72.2%
From 52W high
−72.2%
From 52W low
+32.7%
$0.35
$1.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HUMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Humacyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
17/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
71
Issuance
61
Accruals
53
Growth
51
Revisions
30
Quality
19
Value
13
Volatility
8
Momentum
6

Size (71): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HUMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HUMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26HUMAHigh $4.00Median $1.13Low $0.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
4 Buy2 Hold0 Sell
Low $0.50Median $1.13High $4.00

The green dot is the last close — the median target sits +139.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
7 Oct 2026BarclaysInitiatesEqual-Weight$0.50
13 Aug 2026BenchmarkMaintainsSpeculative Buy—
13 Aug 2026BenchmarkMaintainsSpeculative Buy$2.00 → $1.00
28 July 2026BTIGReiteratesBuy—
28 July 2026BTIGReiteratesBuy$2.00
17 June 2026TD CowenMaintainsBuy—
17 June 2026TD CowenMaintainsBuy$1.50 → $1.25
16 June 2026BTIGReiteratesBuy—
16 June 2026BTIGReiteratesBuy$2.00
11 June 2026HC Wainwright & Co.MaintainsBuy$3.00 → $4.00
11 June 2026HC Wainwright & Co.MaintainsBuy—
8 June 2026BTIGReiteratesBuy—
1 June 2026BenchmarkMaintainsSpeculative Buy—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026TD CowenMaintainsBuy—
13 May 2026BTIGMaintainsBuy—
28 Apr 2026BTIGReiteratesBuy—
28 Apr 2026D. Boral CapitalMaintainsBuy—
24 Apr 2026D. Boral CapitalMaintainsBuy—
21 Apr 2026D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

HUMA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HUMA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Humacyte, Inc. returned −72.2% against +13.1% for the S&P 500, dividends included.

HUMA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26HUMAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HUMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Humacyte, Inc. (HUMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 86% of US stocks

Price / sales
61.6×

Cheaper than 5% of US stocks

Price / book
4.2×

Cheaper than 23% of US stocks

EV / EBITDA
−1.1×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
34.9%

Higher than 80% of US stocks

Earnings growth (YoY)
34.9%

Higher than 68% of US stocks

Gross margin
−203.2%

Higher than 1% of US stocks

Operating margin
−6649.3%

Higher than 2% of US stocks

Net margin
−376.1%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−547.9%

Higher than 3% of US stocks

Return on assets
−49.9%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Humacyte, Inc. (HUMA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Humacyte, Inc. has a market value of $130.6M and an enterprise value of $117.6M.

  • Revenue in the twelve months to 30 June 2026: $2.1M. The latest quarter grew 34.9% year on year.

  • Net income over the same four quarters: −$96.7M, a −4560.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$97.6M.

  • Shares outstanding: 277.8M.

  • Trailing P/E: −1.8×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Humacyte, Inc. employs 184 people — $12K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

HUMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HUMAHumacyte, Inc.$130.6M17
HURATuHURA Biosciences, Inc.$125.1M16
FHTXFoghorn Therapeutics, Inc.$122.4M40
CDXSCodexis, Inc.$131.2M63
AVXLAnavex Life Sciences Corp.$120.5M22
OTLKOutlook Therapeutics, Inc.$120.1M4
CHRSCoherus Oncology, Inc.$134.3M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Humacyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HUMA news & analysis

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

GlobeNewsWire · 28 Oct 2026positive

Humacyte announced the issuance of a new U.S. patent covering Symvess and other bioengineered tissues. The patent provides coverage into 2043 for key aspects of manufacturing, sterilizing, storing, and shipping Symvess.

Why it matters — The patent extends intellectual property coverage for processes related to Symvess, a product relevant to HUMA watchers.

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

GlobeNewsWire · 23 Oct 2026positive

At ASN Kidney Week, Dr. Roy-Chaudhury said results from a Phase 3 trial designed for women support reconsidering access decisions and identify ATEV as a potential option once approved by the FDA.

Why it matters — The comments highlight a potential clinical role for Humacyte’s ATEV in women, while FDA approval remains a condition.

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Zacks Investment Research · 21 Oct 2026positive

Humacyte, Inc. (HUMA) closed at $0.41, up 1.28% from the prior trading day.

Why it matters — The item reports HUMA’s latest closing price and daily change, providing a brief update on its trading session.

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

GlobeNewsWire · 15 Oct 2026positive

Humacyte reported that hospitals ordering Symvess increased 44% in the third quarter, rising from 34 at the end of the second quarter to 49 as of September 30, 2026. The company cited expanding hospital orders and surgeon interest as drivers of continued commercial momentum.

Why it matters — The increase in hospital orders provides an update on Symvess adoption and commercial progress that HUMA watchers may monitor.

FAQ

Frequently asked questions about HUMA stock

What is the HUMA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Humacyte, Inc. have a median 12-month price target of $1.13, with estimates ranging from $0.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HUMA stock a buy right now?

Of the 6 analysts covering Humacyte, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Humacyte, Inc. 17 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HUMA?

As at 29 Oct 2026, Humacyte, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).

Will HUMA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +139.5% from the last close, and Ticker Nerd's factor model ranks Humacyte, Inc. 17 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HUMA stock forecast for 2030?

No analyst covering Humacyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HUMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.5 to $4 over the next 12 months.

How has HUMA stock performed over the past year?

Humacyte, Inc. returned -72.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Humacyte, Inc. do?

Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable.

What is the latest news on HUMA?

The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues". Humacyte announced the issuance of a new U.S. patent covering Symvess and other bioengineered tissues. The patent provides coverage into 2043 for key aspects of manufacturing, sterilizing, storing, and shipping Symvess.

Company

About Humacyte, Inc.

Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable. Its core platform centers on acellular tissue technologies, including human acellular vessels, that are intended to support vascular repair and reconstruction across multiple medical settings. The company’s products and programs address critical needs in areas such as vascular trauma, hemodialysis access, peripheral arterial disease, and other regenerative medicine applications. Humacyte also works on advanced tissue constructs and organ systems, positioning its technology at the intersection of regenerative medicine, bioengineering, and surgical care. Headquartered in Durham, North Carolina, Humacyte serves the healthcare market through its commercial-stage development and manufacturing capabilities.

CEO Dr. Laura E. Niklason M.D., Ph.D. · 184 employees · United States · https://www.humacyte.com